Drug Trial Radar · NCT04471298
A Study of Qishenyiqi Dripping Pills in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Jul 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Sep 21, 2020
Primary completion
Jan 11, 2021
Study completion Jan 11, 2021
Sponsor
- Lead sponsor
- Tasly Pharmaceutical Group Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and tolerability of Qishenyiqi Dripping Pills in healthy participants, following oral administration with multiple escalating dose of it.
Conditions
- Healthy Participants
Interventions
Qishenyiqi dripping pills, 6 bagsDrug
28 consecutive days
Qishenyiqi dripping pills, 9 bagsDrug
28 consecutive days
Qishenyiqi dripping pills, 12 bagsDrug
28 consecutive days
Qishenyiqi dripping pills placebo, 6 bagsDrug
28 consecutive days
Qishenyiqi dripping pills placebo, 9 bagsDrug
28 consecutive days
Qishenyiqi dripping pills placebo, 12 bagsDrug
28 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: From screening (2 weeks in advance) till follow-up visit (up to 1week)
- Number of participants with abnormal vital signs index (body temperature)Time frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
- Number of participants with abnormal vital signs index (pulse rate)Time frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
- Number of participants with abnormal vital signs index (respiratory rate)Time frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
- Number of participants with abnormal vital signs index (blood pressure)Time frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
- Physical examinationTime frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
- Number of participants with abnormal laboratory assessments (blood routine test)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
- Number of participants with abnormal laboratory assessments (blood biochemical test)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
- Number of participants with abnormal laboratory assessments (coagulation function test)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
- Number of participants with abnormal laboratory assessments (urinalysis routine test)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
- Number of participants with abnormal laboratory assessments (fecal routine test)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
- Number of participants with abnormal findings in 12-lead safety Electrocardiogram (ECG)Time frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Teaching Hospital of Tianjin University of TCM
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.